Hamburg, Germany-based specialty chemical, medical products and cosmetics group Beiersdorf AG says that for the first six months of 1994 it has produced sales of 2.67 billion Deut-schemarks ($1.7 billion), a rise of 10% on the like, year-earlier period. The increase is attributed to corporate consolidations, without which it would have been only 7.5%. Although figures are not released, Beiersdorf says that operating profits for the first half of the year increased at a faster rate than sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze